Inhibrx Biosciences, Inc. (INBX) stock
INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$74.18−3.48 (-4.48%)
Close on Nov 17, 2026Market cap $1.09BP/E –Yield –
Inhibrx Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Inhibrx Biosciences's price to sales ratio was 348.3× on Sep 30, 2025, against 334.4× a year earlier. Over the last 4 years it ranged from 13.6× to 390.0×, with a median of 50.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Sep 30, 2025 | 348.3× | +219.7 |
| 2024 | Dec 31, 2024 | 128.6× | −153.4 |
| 2023 | Oct 31, 2023 | 281.9× | +231.5 |
| 2022 | Dec 30, 2022 | 50.4× | −7.5 |
| 2021 | Dec 31, 2021 | 57.9× | +28.0 |
| 2020 | Dec 31, 2020 | 30.0× | – |
See a number that looks wrong?